Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Why Reata (RETA) Stock Might be a Great Pick
09:50am, Tuesday, 07'th Apr 2020
Reata (RETA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations
04:05pm, Monday, 30'th Mar 2020
ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS
Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?
11:30am, Friday, 20'th Mar 2020
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2019 Results - Earnings Call Transcript
08:49pm, Wednesday, 19'th Feb 2020
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2019 Results - Earnings Call Transcript
Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter
11:28am, Tuesday, 04'th Feb 2020
The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2019 portfolio late last week, listing four new holdings.
How A Rumored Amgen Takeover Sent This Biotech Stock Popping
11:12am, Friday, 31'st Jan 2020
Shares of Reata Pharmaceuticals jumped Friday on reports suggesting Amgen could be interested in acquiring the smaller biotech company. Reata is working on a key kidney disease treatment.
Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases: What it Means for Investors
09:15am, Tuesday, 26'th Nov 2019
The capital sets the biotech up nicely to launch two successful drugs.
PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering
07:15pm, Wednesday, 13'th Nov 2019
PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing
Reata Pharmaceuticals (RETA) CEO Warren Huff Discusses Positive Topline Pivotal Year 1 CARDINAL Data (Transcript)
09:31pm, Tuesday, 12'th Nov 2019
Reata Pharmaceuticals (RETA) CEO Warren Huff Discusses Positive Topline Pivotal Year 1 CARDINAL Data (Transcript)
Reata Pharmaceuticals: Confusion On The Secondary Endpoint
07:18pm, Tuesday, 12'th Nov 2019
Reata Pharmaceuticals: Confusion On The Secondary Endpoint
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates
07:55am, Tuesday, 12'th Nov 2019
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019.
Why Shares of Reata Pharmaceuticals Rocketed More Than 150% in October
12:02am, Tuesday, 12'th Nov 2019
A drug trial showed promise in treating a particularly stubborn disease.
This Biotech Has Rocketed 181% Since October — Did It Just Tap Out?
05:15pm, Monday, 11'th Nov 2019
Shares of Reata Pharmaceuticals were briefly halted late Monday just before the biotech company confirmed a recently reacquired kidney disease drug succeeded in a Phase 3 study.
Reata Pharma kidney drug meets study goals, stock halted
04:23pm, Monday, 11'th Nov 2019
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study.
